TY - JOUR
T1 - Protein Phosphatase Inhibitor-1 and Inhibitor-2 from Rabbit Skeletal Muscle
AU - Cohen, Philip
AU - Gordon Foulkes, J.
AU - Holmes, Charles F.B.
AU - Nimmo, Gillian A.
AU - Tonks, Nicholas K.
PY - 1988
Y1 - 1988
N2 - Protein Phosphatase inhibitor-I becomes inhibitory toward protein phosphatase-I only when it has been phosphorylated by cAMPdependent protein kinase, and is likely to play an important role in the control of glycogen metabolism by epinephrine in skeletal muscle. Inhibitor- 2 is a subunit of the cytosolic form of protein phosphatase-l, termed phosphatase-11. Inhibitor-1 and inhibitor-2 are assayed by their ability to inhibit the dephosphorylation of phosphorylase a catalyzed by the free catalytic subtunit of protein phosphatase-1. They are effective at nanomolar levels, which is similar to the concentration of protein phosphatase-1 in the assays. Consequently, the extent of inhibition decreases as the concentration of protein phosphatase-1 increases and vice versa. It is, therefore, important to standardize the protein phosphatase concentration in the assays. Inhibitor-1 is in its dephosphorylated form at each stage of the preparation and must, therefore, be phosphorylated prior to assay. Inhibitor-2 is also diluted in solution A + 0.03% (w/v) Brij-35 and assayed in an identical manner to inhibitor-l, except that prior phosphorylation with cAMP-dependent protein kinase is omitted, and preincubation with protein phosphatase-1 is for 10 rather than 2 min, before addition of 32p-labeled phosphorylase a.
AB - Protein Phosphatase inhibitor-I becomes inhibitory toward protein phosphatase-I only when it has been phosphorylated by cAMPdependent protein kinase, and is likely to play an important role in the control of glycogen metabolism by epinephrine in skeletal muscle. Inhibitor- 2 is a subunit of the cytosolic form of protein phosphatase-l, termed phosphatase-11. Inhibitor-1 and inhibitor-2 are assayed by their ability to inhibit the dephosphorylation of phosphorylase a catalyzed by the free catalytic subtunit of protein phosphatase-1. They are effective at nanomolar levels, which is similar to the concentration of protein phosphatase-1 in the assays. Consequently, the extent of inhibition decreases as the concentration of protein phosphatase-1 increases and vice versa. It is, therefore, important to standardize the protein phosphatase concentration in the assays. Inhibitor-1 is in its dephosphorylated form at each stage of the preparation and must, therefore, be phosphorylated prior to assay. Inhibitor-2 is also diluted in solution A + 0.03% (w/v) Brij-35 and assayed in an identical manner to inhibitor-l, except that prior phosphorylation with cAMP-dependent protein kinase is omitted, and preincubation with protein phosphatase-1 is for 10 rather than 2 min, before addition of 32p-labeled phosphorylase a.
UR - http://www.scopus.com/inward/record.url?scp=0023696487&partnerID=8YFLogxK
U2 - 10.1016/0076-6879(88)59042-0
DO - 10.1016/0076-6879(88)59042-0
M3 - Article
C2 - 2842607
AN - SCOPUS:0023696487
SN - 0076-6879
VL - 159
SP - 427
EP - 437
JO - Methods in Enzymology
JF - Methods in Enzymology
IS - C
ER -